At the time of exit, Atrium was a globally recognised leader in the development, manufacturing and commercialisation of innovative, science-based health products including vitamins, minerals and nutritional supplements.

The company developed, manufactured and distributed more than 2,000 health and nutrition products through four primary brands with leading positions in North America and Europe. Atrium had the leading natural product brand in the US, Garden of Life, and a top-three position in the North American healthcare practitioner channel led by the Pure and Douglas brands.

The company also operated a European business, based in Germany, primarily under the Wobenzym name.